DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Polatuzumab vedotin
Polatuzumab vedotin
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
Australian Public Assessment for Polatuzumab Vedotin
Pharmacokinetics of Polatuzumab Vedotin in Combination with R/G‑CHP in Patients with B‑Cell Non‑Hodgkin Lymphoma
Antibody–Drug Conjugates
Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of a Phase Ib/II Trial
A Phase Ib/II Study Evaluating the Safety and Efficacy Of
Antibody–Drug Conjugates: the Last Decade
New Drug Updates Brendan Mangan, Pharmd Clinical Pharmacy Specialist Hospital of the University of Pennsylvania
Immunotherapies Shape the Treatment Landscape for Hematologic Malignancies Jane De Lartigue, Phd
Event Analysis of Polatuzumab Vedotin‐Induced Peripheral
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Polivy™ (Polatuzumab Vedotin-Piiq) (Intravenous) Document Number: IC-0482 Last Review Date: 09/03/2019 Date of Origin: 07/01/2019 Dates Reviewed: 07/2019, 09/2019
Phase II Data Showed Roche's Investigational Polatuzumab
Antibody Drug Conjugates for Cancer Treatment
Roche Analyst Event Monday, 5 December 2016 This Presentation Contains Certain Forward-Looking Statements
Immune Therapies for Hematologic Malignancies
Polatuzumab Vedotin-Piiq (Polivy™)
Top View
Antibody–Drug Conjugates for Cancer Therapy
View of This Manuscript
Polatuzumab Vedotin in 16 Patients Compared with Seven Patients Who Responded to Bendamustine and Rituximab
Oncology Dose Reduction Program Beginning July 1, 2021
Enfortumab Vedotin for Locally Advanced Or Metastatic Urothelial
Banner Health Network Medical Oncology Code List
FDA Grants Priority Review to Roche's Polatuzumab Vedotin in Previously
Polatuzumab Vedotin in Combination with Rituximab and Bendamustine for the Treatment of Diffuse Large B-Cell Lymphoma
Clinical Trials Highlights
Enfortumab Vedotin-Ievx) NDA/BLA Multi-Disciplinary Review and Evaluation
Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
Monoclonal Antibody Pharmacogenomics in Cancer Treatment
The Oncology Market for Antibody–Drug Conjugates
Cardiotoxicity of Novel Targeted Hematological Therapies
Polivy Product Monograph
Antibody–Drug Conjugates in Solid Tumors: a Look Into Novel Targets Carmen Criscitiello1,2, Stefania Morganti1,2 and Giuseppe Curigliano1,2*
Polatuzumab Vedotin (Interim Monograph)
Obinutuzumab for the Treatment of Non-Hodgkin Lymphomas
(POLIVY®) Antibody–Drug Conjugate in Sprague Dawley Rats
Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-POLATUZUMAB
An Overview of Antibody–Drug Conjugates in Oncological Practice
New Agents and Regimens for Diffuse Large B Cell Lymphoma
Pandora's Box: 2019 Oncology and Hematology Drugs
Polivy, INN-Polatuzumab Vedotin
VIRGINIA Provider Communications
Targeting Selectins, Siglecs and Mammalian Glycans
New Century Health Policy Changes March 2021
(SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma
Polatuzumab Vedotin-Piiq
Polatuzumab Vedotin-Piiq) for Injection, for Intravenous Use Infection
Fda 131 ° 48 36 # Both* 20 13 8 Ema 126 30 29
Cutaneous Toxicity Associated with Enfortumab Vedotin Treatment of Metastatic Urothelial Carcinoma
Clinical Pharmacology Strategies in Supporting Drug Development and Approval of Antibody–Drug Conjugates in Oncology
PDF of Antibody News
Anti-CD22 and Anti-CD79B Antibody Drug Conjugates Are Active in Different Molecular Diffuse Large B-Cell Lymphoma Subtypes
EFPIA Pipeline Review 2021 Update
Polatuzumab Vedotin with Rituximab and Bendamustine for Treating Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
QUICK FACTS Commercialization Agreement with Merck for LV in Breast Cancer and Other Solid Tumors
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Polatuzumab Vedotin-Piiq) in RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER TWO PRIOR THERAPIES
Aacr Cancer Progress Report
Codes Drug Name J3262 Actemra
Novel Therapies for Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
New Drug Updates in Hematologic Malignancies
761121Orig1s000
Understanding Immunotherapy and Lymphoma
761121Orig1s000
Severe Treatment-Refractory T-Cell-Mediated Immune Skin
Symbio Receives Approval for Use of TREAKISYM® in Combination With
Assessment Report: Polivy
A Phase Ib/Ii Study Evaluating the Safety
761121Orig1s000